Travere Therapeutics (17R) Risk Analysis
Risk Overview Q2, 2026
Source: the company's latest filing for the period ended Jun 30, 2026, filed Aug 04, 2026
Risk Change Over Time
- Debt & Financing - Risk 1We may be unable to raise the funds necessary to repurchase the 2029 Notes and 2032 Notes for cash following a fundamental change, or to pay any cash amounts due upon conversion, and our future indebtedness may limit our ability to repurchase the 2029 Notes and 2032 Notes or pay cash upon their conversion.*
Noteholders may require us to repurchase their 2029 Notes or 2032 Notes, as applicable, following a fundamental change at a cash repurchase price generally equal to the principal amount of the 2029 Notes and 2032 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, upon conversion of the 2029 Notes or the 2032 Notes, we may be required or elect to satisfy all or a portion of our conversion obligation in cash, shares of our common stock or a combination thereof, depending on the terms of the applicable notes and any settlement election we make. We may not have enough available cash or be able to obtain financing at the time we are required to repurchase the 2029 Notes or 2032 Notes, or pay the cash amounts due upon conversion thereof. In addition, applicable law, regulatory authorities and the agreements governing our future indebtedness may restrict our ability to repurchase the 2029 Notes or 2032 Notes or pay the cash amounts due upon conversion thereof. Our failure to repurchase the 2029 Notes or 2032 Notes or to pay the cash amounts due upon conversion thereof when required will constitute a default under the base and supplemental indentures that govern the 2029 Notes and 2032 Notes, which we refer to collectively as the "indenture." We may not have sufficient funds to satisfy all amounts due under the 2029 Notes, the 2032 Notes and any other indebtedness.
- Debt & Financing - Risk 2A default under the 2029 Notes or 2032 Notes may have a material adverse effect on our financial condition.*
If an event of default under the 2029 Notes or 2032 Notes occurs, the principal amount of the 2029 Notes or 2032 Notes, as applicable, plus accrued and unpaid interest (including additional interest, if any) may be declared immediately due and payable, subject to certain conditions set forth in the indenture governing such notes. Events of default under the indentures governing the 2029 Notes and the 2032 Notes include, among other things: - certain failures to make required payments of principal or interest;- certain failures to comply with conversion, notice or other covenant obligations;- specified defaults or accelerations with respect to other indebtedness; and - certain bankruptcy, insolvency or reorganization events. Accordingly, the occurrence of a default under the 2029 Notes or 2032 Notes, unless cured or waived, may have a material adverse effect on our results of operations.
- Debt & Financing - Risk 3Provisions of the 2029 Notes and 2032 Notes could discourage an acquisition of us by a third party.*
Certain provisions of the 2029 Notes and 2032 Notes could make it more difficult or more expensive for a third party to acquire us. Upon the occurrence of certain transactions constituting a fundamental change, under the applicable indenture governing the 2029 Notes and 2032 Notes, holders of the 2029 Notes or 2032 Notes, as the case may be, will have the right, at their option, to require us to repurchase all of their notes or any portion of the principal amount of such notes in integral multiples of $1,000. We may also be required to increase the conversion rate for conversions of the 2029 Notes and/or 2032 Notes, as applicable, in connection with certain make-whole fundamental changes.
- Debt & Financing - Risk 4Conversion of the 2029 Notes or 2032 Notes may dilute the ownership interest of existing stockholders, including holders who had previously converted their 2029 Notes or 2032 Notes.*
To the extent we issue shares of common stock upon conversion of the 2029 Notes or the 2032 Notes, the conversion of some or all of such notes may dilute the ownership interests of existing stockholders. Any sales in the public market of shares of the common stock issuable upon such conversion could adversely affect prevailing market prices of shares of our common stock. In addition, the existence of the 2029 Notes and 2032 Notes may encourage short selling by market participants because the conversion of the notes could be used to satisfy short positions, which could depress the price of shares of our common stock.
Risk Highlights Q2, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 61
- Share Price & Shareholder Rights - Risk 1The market price for shares of our common stock may be volatile and purchasers of our common stock could incur substantial losses.
The price of our stock is likely to be volatile. The stock market in general, and the market for biotechnology companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock has been in the past, and may be in the future, influenced by many factors, including: - results of clinical trials of our product candidates or those of our competitors;- our entry into or the loss of a significant collaboration;- regulatory or legal developments in the United States and other countries, including changes in the health care payment systems;- our ability to obtain and maintain marketing approvals from the FDA or similar regulatory authorities outside the United States;- variations in our financial results or those of companies that are perceived to be similar to us;- changes in the structure of healthcare payment systems;- market conditions in the pharmaceutical and biotechnology sectors and issuance of new or changed securities analysts' reports or recommendations;- general economic, industry and market conditions, including the impacts thereon of inflation and high interest rates, actual or anticipated bank failures, new or increased tariffs, wars, armed conflicts and global geopolitical tensions;- results of clinical trials conducted by others on therapies that would compete with our product candidates;- developments or disputes concerning patents or other proprietary rights;- public concern over our product candidates or any products approved in the future;- litigation;- communications from government officials regarding health care costs or pharmaceutical pricing;- future sales or anticipated sales of our common stock by us or our stockholders; and - the other factors described in this "Risk Factors" section. In addition, the stock markets, and in particular, the Nasdaq Stock Market, have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many pharmaceutical companies. The realization of any of the above risks or any of a broad range of other risks, including those described in these "Risk Factors" could have a dramatic and material adverse impact on the market price of our common stock.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.